Search contract descriptions, companies and agencies.
DEVELOP A SAFE AND EFFECTIVE THERAPEUTIC TO MITIGATE SEVERE OUTCOMES, INCLUDING BUT NOT LIMITED TO MORTALITY, IN PATIENTS WITH SEVERE INFECTION OR SEPSIS OF ANY ETIOLOGY.
Total Committed
$749K
Product or Service Description
Biomedical Advanced Development R&D
Total Potential Value
$749K
Contracting Agency
Effective Date
June 11, 2021
Funding Department
BARDA - ASPR / DAAPPO / BARDA DCMA
Type
Firm fixed price
Solicitation Procedure
Negotiated proposal/quote
Extent Competed
Full and open competition
Recent Contract Actions 
Contracts can have multiple “contract actions”: This is how agencies spend money for a specific purpose, adjust the amount committed or change the contract in a way that doesn’t affect the amount. That last scenario is usually indicated by a $0 action. If there is a contract action for a negative amount, it generally means the contract was adjusted or canceled.
| Vendor | Description | Signed | Reason for Change | Amount Committed |
|---|---|---|---|---|
| BIOAEGIS THERAPEUTICS INC | DEVELOP A SAFE AND EFFECTIVE THERAPEUTIC TO MITIGATE SEVERE OUTCOMES, INCLUDING BUT NOT LIMITED TO MORTALITY, IN PATIENTS WITH SEVERE INFECTION OR SEPSIS OF ANY ETIOLOGY. | June 11, 2021 | $749,000 |
About this data
This data comes from the Federal Procurement Data System, which includes all contracts worth $10,000 or more. We look at all contracts that are tagged with the procurement code for COVID-19 or otherwise started in 2020 and contain “COVID-19” in the description. Department of Defense contracting data is subject to a 90-day delay before it appears in the data.